FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted-Reference-Cited by-同舟云学术

FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted

Published:2021-08 Issue:2 Volume:75 Page:363-376
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Vallejo Adrián,Erice Oihane,Entrialgo-Cadierno Rodrigo,Feliu Iker,Guruceaga Elizabeth,Perugorria Maria J.,Olaizola Paula,Muggli Alexandra,Macaya Irati,O’Dell Michael,Ruiz-Fernandez de Cordoba Borja,Ortiz-Espinosa Sergio,Hezel Aram F.,Arozarena Imanol,Lecanda Fernando,Avila Matias A.,Fernandez-Barrena Maite G.,Evert Matthias,Ponz-Sarvise Mariano,Calvisi Diego F.,Banales Jesus M.,Vicent Silve

Funder

Caja Navarra Foundation

Fundacion Cientifica de la Asociacion Espaoola Contra el Cancer

Gobierno de Navarra Departamento de Educacion

Carlos III Health Institute

Publisher

Elsevier BV

Subject

Hepatology

Reference60 articles.

1. Cholangiocarcinoma 2020: the next horizon in mechanisms and management;Banales;Nat Rev Gastroenterol Hepatol,2020

2. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma;Borad;PloS Genet,2014